Application of nurse-patient interaction integrated APP in patients with neuroendocrine tumors treated with long-acting octreotide

XU Xin; LI Na; SANG Ni; ZHU Zihui; QIN Xian; HAN Qianqian; ZHANG Jingjing; ZHU Ling

doi:10.7619/jcmp.20232687

Journal of Clinical Medicine in Practice > 2023 > 27(22): 127-130, 137. > DOI: 10.7619/jcmp.20232687

XU Xin, LI Na, SANG Ni, ZHU Zihui, QIN Xian, HAN Qianqian, ZHANG Jingjing, ZHU Ling. Application of nurse-patient interaction integrated APP in patients with neuroendocrine tumors treated with long-acting octreotide[J]. Journal of Clinical Medicine in Practice, 2023, 27(22): 127-130, 137. DOI: 10.7619/jcmp.20232687

Citation:

PDF (794 KB)

Application of nurse-patient interaction integrated APP in patients with neuroendocrine tumors treated with long-acting octreotide

Department of Geriatric Nerve and Gastroenterology, Jiangsu Provincial People's Hospital, the First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, 210029

More Information

Received Date: August 23, 2023
Revised Date: November 21, 2023
Available Online: December 05, 2023

Graphical Abstract

Abstract

Abstract

Objective
To develop a nurse-patient interaction integrated APP "NET Home" to provide detailed care and follow-up management for patients with neuroendocrine tumors (NENs) treated with long-acting octreotide.
Methods
"NET Home" APP included three ports: patient side, medical side and management side. After discharge, NENs patients timely and comprehensive fed back on adverse reactions and discomfort symptoms through APP, and medical staff timely guided patients to deal with them online.
Results
At 1 year after "NET Home" APP application, 45 patients registered (injected with long-acting octreotide once every 28 days). A total of 145 copies of Micro-nutrition Evaluation Scales, 147 Tumor Patients' Quality of Life Rating scales, 102 Pain Digital Evaluation Scales, 103 Adverse Reactions Questionnaire of Long-acting Octreotide Injection, 102 Self-care Ability Scales, 111 Self-rating Scales for depression and 102 Self-rating Scales for anxiety were collected. The medical staff treated 5 cases of adverse reactions by APP, and gave timely handling to 1 case of severe adverse reactions (the patient eventually stopped long-acting octreotide therapy). Compared with NENs patients who did not use APP, anxiety scores of NENs patients who used APP decreased (P < 0.05); their satisfaction scores and quality of life scores were improved, and the number of unplanned admissions decreased, but the differences showed no statistically significant (P > 0.05).
Conclusion
"NET Home" APP can realize refined and personalized nursing intervention through multiple module functions, which can realize continuous home care for NENs patients, relieve their anxiety and improve their self-management ability, quality of life and treatment compliance.
- APP,
- long-acting octreotide,
- neuroendocrine neoplasms,
- refined care,
- self-management ability,
- continuous nursing

FullText(HTML)

References (16)

References

[1]	杨欢, 王晓坤, 石素胜, 等. 不同年龄胃肠胰神经内分泌肿瘤患者预后分析[J]. 中国肿瘤临床, 2022, 49(15): 792-796. doi: 10.12354/j.issn.1000-8179.2022.20220089
[2]	DASARI A, SHEN C, HALPERIN D, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States[J]. JAMA Oncol, 2017, 3(10): 1335. doi: 10.1001/jamaoncol.2017.0589
[3]	CIVES M, STROSBERG J R. Gastroenteropancreatic neuroendocrine tumors[J]. CA Cancer J Clin, 2018, 68(6): 471-487. doi: 10.3322/caac.21493
[4]	SHAH M H, GOLDNER W S, HALFDANARSON T R, et al. NCCN guidelines insights: neuroendocrine and adrenal tumors, version 2. 2018[J]. J Natl Compr Canc Netw, 2018, 16(6): 693-702. doi: 10.6004/jnccn.2018.0056
[5]	中国抗癌协会神经内分泌肿瘤专业委员会. 中国抗癌协会神经内分泌肿瘤整合诊治指南(精简版)[J]. 中国肿瘤临床, 2023, 50(8): 385-397. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGZL202317002.htm
[6]	高鹤丽, 徐近, 虞先濬. 2021年胰腺神经内分泌肿瘤诊治的新进展[J]. 中国癌症杂志, 2022, 32(9): 772-778. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGAZ202209003.htm
[7]	甘恬田, 张长霞, 姚晓琴. 胰腺神经内分泌肿瘤病人手术后应用长效奥曲肽的护理效果分析[J]. 实用临床护理学电子杂志, 2019, 4(23): 34-34, 42. https://www.cnki.com.cn/Article/CJFDTOTAL-SLHL201923027.htm
[8]	CAPLIN M E, PAVEL M, CWIKŁA J B, et al. Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study[J]. Endocr Relat Cancer, 2016, 23(3): 191-199. doi: 10.1530/ERC-15-0490
[9]	CAPLIN M E, PAVEL M, PHAN A T, et al. Lanreotide autogel/depot in advanced enteropancreatic neuroendocrine tumours: final results of the CLARINET open-label extension study[J]. Endocrine, 2021, 71(2): 502-513. doi: 10.1007/s12020-020-02475-2
[10]	李明明, 白岩. 醋酸奥曲肽微球联合吉西他滨对胃肠胰神经内分泌肿瘤患者血清激素、肿瘤标志物水平及预后的影响[J]. 检验医学与临床, 2022, 19(16): 2250-2255. https://www.cnki.com.cn/Article/CJFDTOTAL-JYYL202216023.htm
[11]	PAVEL M, CWIKŁA J B, LOMBARD-BOHAS C, et al. Efficacy and safety of high-dose lanreotide autogel in patients with progressive pancreatic or midgut neuroendocrine tumours: clarinet FORTE phase 2 study results[J]. Eur J Cancer, 2021, 157: 403-414. doi: 10.1016/j.ejca.2021.06.056
[12]	孔颖, 黄婷, 沈萌. 基于移动医疗App的延续性护理对慢性鼻窦炎患者的影响[J]. 齐鲁护理杂志, 2020, 26(3): 32-35. https://www.cnki.com.cn/Article/CJFDTOTAL-QLHL202003013.htm
[13]	陈晓敏, 胡英杰, 陈玲, 等. 基于移动医疗的孕期盆底肌训练方案的构建[J]. 中国全科医学, 2020, 23(30): 3806-3811. https://www.cnki.com.cn/Article/CJFDTOTAL-QKYX202030008.htm
[14]	张瑞玲, 王玉英, 郭建琳, 等. 基于移动医疗APP的HIV感染病人远程延续护理模式的构建与应用[J]. 护理研究, 2022, 36(3): 517-521. https://www.cnki.com.cn/Article/CJFDTOTAL-SXHZ202203026.htm
[15]	HWANG R, MORRIS N R, MANDRUSIAK A, et al. Cost-utility analysis of home-based telerehabilitation compared with centre-based rehabilitation in patients with heart failure[J]. Heart Lung Circ, 2019, 28(12): 1795-1803.
[16]	尹瑶, 陈红. 痛风病人自我管理移动医疗应用程序研究进展[J]. 护理研究, 2021, 35(16): 2926-2929. https://www.cnki.com.cn/Article/CJFDTOTAL-SXHZ202116021.htm

Cited By

Get Citation

PDF

XML

Article views (112) PDF downloads (5)

Turn off MathJax

Article Contents

Abstract

References

Application of nurse-patient interaction integrated APP in patients with neuroendocrine tumors treated with long-acting octreotide

Abstract

References

Catalog

Export File

Citation

Format

Content